Medpace Holdings Inc., a contract research organization, reported strong second-quarter 2025 financial results, with earnings per share (EPS) of $3.10 and revenue of $603.3 million, both exceeding market expectations. The company posted a net income of $90.3 million and secured a record $621 million in net new business awards, driving its book-to-bill ratio to 1.03, indicating sustained growth momentum. Following the earnings release, Medpace's stock surged by approximately 40% to 45% in after-hours trading. The company also raised its full-year 2025 revenue and EPS guidance in response to the robust new business performance.